Anifrolumab dosage and usage guidance

Anifrolumab (Anifrolumab, trade name Saphnelo) is a new biological agent for the treatment of systemic lupus erythematosus (SLE). It is a type I interferon receptor antagonist. It specifically binds to subunit 1 of the type I interferon receptor and effectively blocks the activity of signaling molecules such as IFN-α, IFN-β and IFN-ω, thereby inhibiting the immune response closely related to the onset of SLE and providing a new treatment option for SLE patients.

In terms of usage and dosage, for adult patients with systemic lupus erythematosus, the recommended dose of anilumab is an intravenous infusion every 4 weeks, with each infusion volume being 300 mg, and the entire infusion process lasting approximately 30 minutes. The drug is supplied in single-dose vials of 300 mg/2 mL (i.e., with a concentration of 150 mg/mL) for easy clinical use.

It is worth noting that although anilumab has shown good efficacy and safety in most patients with SLE, its efficacy has not been fully evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Therefore, such patients need to be extremely cautious when using anilumab, and it is best to make decisions under the guidance of professional doctors.

The introduction of anilumab marks a major advance in the treatment of systemic lupus erythematosus. Its unique mechanism of action and significant efficacy provide new hope for SLE patients who have failed to respond to traditional treatments or whose disease activity persists. However, as a new drug, the safety and long-term efficacy of anilumab still require further observation and evaluation. Therefore, during use, patients should pay close attention to their own reactions and communicate with their doctors regularly in order to adjust the treatment plan in a timely manner to ensure the best treatment effect.

Reference link: https://www.drugs.com/anifrolumab.html